# Usana Health Sciences Inc: overview

USNA · NYSE · CIK 896264 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 3

Pages: [Overview](/companies/usna.md) · [Financials](/companies/usna/financials.md) · [Filings](/companies/usna/filings.md) · [Insiders](/companies/usna/insiders.md)

Latest reported revenue: [$223.3m](/filings/0000896264-26-000056.md) for Q2 FY2026, three months to 2026-07-04, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000896264-26-000056).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [200](/filings/0000896264-25-000224.md) | [214 d](/filings/0000896264-26-000021.md) | [250](/filings/0000896264-26-000034.md) | [236](/filings/0000896264-26-000056.md) | [214](/filings/0000896264-25-000224.md) | [226 d](/filings/0000896264-26-000021.md) | [250](/filings/0000896264-26-000034.md) | [223](/filings/0000896264-26-000056.md) |
| Gross margin | % | [80.4%](/filings/0000896264-25-000224.md) | [82.0% d](/filings/0000896264-26-000021.md) | [79.0%](/filings/0000896264-26-000034.md) | [78.7%](/filings/0000896264-26-000056.md) | [77.2%](/filings/0000896264-25-000224.md) | [78.2% d](/filings/0000896264-26-000021.md) | [76.2%](/filings/0000896264-26-000034.md) | [78.3%](/filings/0000896264-26-000056.md) |
| Operating margin | % | [7.8%](/filings/0000896264-25-000224.md) | [3.8% d](/filings/0000896264-26-000021.md) | [6.3%](/filings/0000896264-26-000034.md) | [7.1%](/filings/0000896264-26-000056.md) | [0.6%](/filings/0000896264-25-000224.md) | [1.7% d](/filings/0000896264-26-000021.md) | [5.5%](/filings/0000896264-26-000034.md) | [(9.0%)](/filings/0000896264-26-000056.md) |
| Net margin | % | [5.3%](/filings/0000896264-25-000224.md) | [2.1% d](/filings/0000896264-26-000021.md) | [3.8%](/filings/0000896264-26-000034.md) | [4.1%](/filings/0000896264-26-000056.md) | [(3.1%)](/filings/0000896264-25-000224.md) | [(0.8%) d](/filings/0000896264-26-000021.md) | [3.0%](/filings/0000896264-26-000034.md) | [(9.6%)](/filings/0000896264-26-000056.md) |
| Diluted EPS | $ per share | [0.56](/filings/0000896264-25-000224.md) | not reported | [0.49](/filings/0000896264-26-000034.md) | [0.52](/filings/0000896264-26-000056.md) | [(0.36)](/filings/0000896264-25-000224.md) | not reported | [0.41](/filings/0000896264-26-000034.md) | [(1.16)](/filings/0000896264-26-000056.md) |
| Free cash flow | $m | [27.1 d](/filings/0000896264-25-000224.md) | [4.0 d](/filings/0000896264-26-000021.md) | [12.7](/filings/0000896264-26-000034.md) | [7.2 d](/filings/0000896264-26-000056.md) | [(5.2) d](/filings/0000896264-25-000224.md) | [(6.2) d](/filings/0000896264-26-000021.md) | [7.1](/filings/0000896264-26-000034.md) | [20.2 d](/filings/0000896264-26-000056.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2022-01-01) | FY2022 (2022-12-31) | FY2023 (2023-12-30) | FY2024 (2024-12-28) | FY2025 (2026-01-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,186](/filings/0000896264-24-000093.md) | [999](/filings/0000896264-25-000092.md) | [921](/filings/0000896264-26-000021.md) | [855](/filings/0000896264-26-000021.md) | [925](/filings/0000896264-26-000021.md) |
| Gross margin | % | [81.6%](/filings/0000896264-24-000093.md) | [80.6%](/filings/0000896264-25-000092.md) | [80.8%](/filings/0000896264-26-000021.md) | [81.1%](/filings/0000896264-26-000021.md) | [78.3%](/filings/0000896264-26-000021.md) |
| Operating margin | % | [14.3%](/filings/0000896264-24-000093.md) | [10.8%](/filings/0000896264-25-000092.md) | [10.1%](/filings/0000896264-26-000021.md) | [7.8%](/filings/0000896264-26-000021.md) | [4.0%](/filings/0000896264-26-000021.md) |
| Net margin | % | [9.8%](/filings/0000896264-24-000093.md) | [6.9%](/filings/0000896264-25-000092.md) | [6.9%](/filings/0000896264-26-000021.md) | [4.9%](/filings/0000896264-26-000021.md) | [1.2%](/filings/0000896264-26-000021.md) |
| Diluted EPS | $ per share | [5.73](/filings/0000896264-24-000093.md) | [3.59](/filings/0000896264-25-000092.md) | [3.30](/filings/0000896264-26-000021.md) | [2.19](/filings/0000896264-26-000021.md) | [0.58](/filings/0000896264-26-000021.md) |
| Free cash flow | $m | [108](/filings/0000896264-24-000093.md) | [93.5](/filings/0000896264-25-000092.md) | [56.1](/filings/0000896264-26-000021.md) | [50.9](/filings/0000896264-26-000021.md) | [8.5](/filings/0000896264-26-000021.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/usna/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $33.2m | 1,554,189 |  | Added +363,773 |
| [PZENA INVESTMENT MANAGEMENT LLC](/funds/1027796.md) | 2026-06-30 | $25.7m | 1,205,587 |  | Added +96,654 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $20.5m | 958,520 |  | Reduced −59,110 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $17.9m | 837,426 |  | Added +3,203 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $17.3m | 810,074 |  | Unchanged |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $17.3m | 810,074 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.4m | 487,370 |  | Added +8,327 |
| [Creative Planning](/funds/1540235.md) | 2026-06-30 | $8.9m | 417,971 |  | Added +224,823 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $8.7m | 408,086 |  | Added +111,666 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $7.8m | 363,377 |  | Added +25,103 |

## Recent filings

[All 1,624 filings](/companies/usna/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-05 | 20:36 ET | [8-K](/filings/0000896264-26-000060.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000896264-26-000060 |
| 2026-08-13 | 18:37 ET | [10-Q](/filings/0000896264-26-000056.md) | Quarterly report, period 2026-07-04 | 0000896264-26-000056 |
| 2026-08-04 | 20:22 ET | [8-K](/filings/0000896264-26-000050.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000896264-26-000050 |
| 2026-05-20 | 20:24 ET | [8-K](/filings/0000896264-26-000036.md) | 5.07 Shareholder vote results | 0000896264-26-000036 |
| 2026-05-12 | 20:35 ET | [10-Q](/filings/0000896264-26-000034.md) | Quarterly report, period 2026-04-04 | 0000896264-26-000034 |
| 2026-05-05 | 20:17 ET | [8-K](/filings/0000896264-26-000030.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000896264-26-000030 |
| 2026-04-07 | 20:50 ET | [DEF 14A](/filings/0000896264-26-000026.md) | Proxy statement, period 2026-01-03 | 0000896264-26-000026 |
| 2026-03-30 | 01:20 ET | [SCHEDULE 13D/A](/filings/0001104659-26-037181.md) | Ownership report, active investor, amended | 0001104659-26-037181 |
| 2026-03-16 | 18:57 ET | [10-K](/filings/0000896264-26-000021.md) | Annual report, period 2026-01-03 | 0000896264-26-000021 |
| 2026-02-18 | 01:33 ET | [8-K](/filings/0000896264-26-000014.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000896264-26-000014 |

## Latest annual report

[Form 10-K for the fiscal year ended Jan 3, 2026](/filings/0000896264-26-000021.md), filed Mar 16, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 896264
- Tickers: USNA
- Exchange: NYSE
- SIC code: 2833 Medicinal Chemicals & Botanical Products
- State of incorporation: UT
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.